About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Bad news for Eli Lilly (LLY -7.27%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, and gave new guidance for 2025 revenue as well -- and while its 2025 prediction was a bit more than Wall Street had expected, its prediction for 2024 was a bit less.As of 10:45 a.m. ET, Lilly shares are shedding 6%. Archrival Novo Nordisk (NVO -5.05%) is down 3.3% in sympathy, while Viking Therapeutics (VKTX -11 ...

The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024.Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations.The drugmaker's shares dropped about 6% in early trading Tuesday.Eli Lilly said it now expects full-year 2024 revenue of about $45 billion. That's lower than the $45.4 billion to $46 billion the company anticipated in October. The new outlook would ...

Eli Lilly and Company TodayLLYEli Lilly and Company$797.17 -2.73 (-0.34%) 52-Week Range$612.70▼$972.53Dividend Yield0.75%P/E Ratio86.18Price Target$1,002.22Add to WatchlistEli Lilly & Co. NYSE: LLY is a major global pharmaceutical company in the medical sector. The company made headlines with its dominant GLP-1 drug, Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. While there are many potential contenders in clinical trials, the current GLP-1 market is a duopoly that Eli Lilly d ...

Eli Lilly expects its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks told Bloomberg TV on Monday.The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year.Eli Lilly is pushing to get the pill to market as it competes with Novo Nordisk and smaller rivals for a major share of the booming weight loss drug market. Eli Lilly's Zepbound and Novo Nordisk's Wegovy dominate the space, but the drugmakers and their competi ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trialSTX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this diseaseINDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company develop ...

Investment Opportunities - Novo Nordisk (NVO) is currently undervalued, presenting a near-term bullish opportunity [1] - Eli Lilly (NYSE: LLY) also offers an exceptional investment opportunity at present [1] Analyst Background - Oliver Rodzianko is an investment analyst specializing in the technology sector, with expertise in AI, semiconductors, software, and renewable energy [1] - Rodzianko focuses on companies with resilient management and lasting competitive advantages [1] - His investment strategy involves value trading at inflection points without leverage and without short interest, typically holding investments for one to two years [1] - Rodzianko employs advanced risk-mitigation strategies to protect against and capitalize on recessions and market crashes [1]

Growth & Outlook - Eli Lilly's total sales are expected to expand 33% in FY24 to $45.44 billion, with FY25 sales projected to climb another 33% to $60.36 billion [3] - Eli Lilly's annual earnings are slated to soar 108% in FY24 to $13.14 per share, with FY25 EPS forecasted to climb another 83% to $24.04 [3] - Novo Nordisk's top line is projected to expand 18% in FY24 and increase another 23% in FY25 to $49.03 billion [4] - Novo Nordisk's annual earnings are projected to rise 18% in FY24 and another 22% in FY25 to $3.89 per share [4] Price Performance - Eli Lilly's stock is up +25% over the last year, roughly matching the S&P 500 [6] - Novo Nordisk shares are down -21% over the last year, attributed to subpar clinical trial results for CagriSema and patent concerns [6] - Over the last three years, Novo Nordisk stock is up more than +60%, trailing Eli Lilly's gains of +200% [7] Product Comparison - Eli Lilly's Zepbound and Novo Nordisk's Wegovy are both once-weekly injectable medications for chronic weight management [10] - Zepbound has shown greater weight loss, helping patients lose an average of 20.2% of their body weight, 47% more effective than Wegovy [2] - Zepbound was approved in November 2023, while Wegovy has been cleared for usage since June 2021 [10] Market Position - Eli Lilly appears to have the advantage in the weight loss drug market, with its stock landing a Zacks Rank 3 (Hold) [12] - Novo Nordisk shares land a Zacks Rank 4 (Sell) based on a trend of declining earnings estimate revisions [9]

Eli Lilly and Company’s (LLY) shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to inventory issues in the third quarter. This led the shares of the company to drop following third-quarter results after a powerful first-half performance.Meanwhile, the overall drug and biotech sector has also done poorly in the past three months after Trump announced the appointment of Robert F. Kennedy Jr., a vac ...